Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nicardipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It has greater selectivity for vascular smooth muscle than for cardiac muscle, leading to vasodilation and reduced peripheral vascular resistance. It does not significantly affect sinoatrial nodal or atrioventricular conduction.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Short-term treatment of hypertension when oral therapy is not feasible or desirable (FDA approved),Prolonged treatment of hypertension in patients unable to take oral medications (off-label),Management of hypertensive emergencies (off-label),Subarachnoid hemorrhage (off-label),Prevention and treatment of cerebral vasospasm (off-label)
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Administer intravenously at an initial rate of 5 mg/h, titrated by increasing by 2.5 mg/h every 5-15 minutes to a maximum of 15 mg/h for hypertension. For substitution of oral therapy, start at 0.5 mg/h and titrate to achieve desired blood pressure.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Terminal elimination half-life is 8.6 hours (range 6-10 hours) in adults with normal hepatic function; prolonged in elderly or hepatic impairment. Clinical context: permits continuous IV infusion for stable hemodynamic control.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Primarily hepatic via cytochrome P450 isoenzymes CYP3A4 and CYP3A5, with minor contributions from CYP2C8. The drug undergoes extensive first-pass metabolism resulting in low oral bioavailability; however, intravenous administration bypasses first-pass metabolism. Metabolites are inactive and excreted primarily in urine (60%) and feces (35%).
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Primarily hepatic metabolism (>90%) with <1% unchanged drug excreted renally. Fecal excretion accounts for approximately 35% of metabolites via biliary elimination.
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
>95% bound to plasma proteins (primarily albumin, alpha-1-acid glycoprotein). High binding limits free drug concentration.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
8.3 L/kg (0.08-0.17 L/kg in some sources; clinical meaning: extensive tissue distribution, particularly in vascular smooth muscle; Vd increases with hepatic impairment).
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Oral: ~35% (first-pass effect); IV: 100% (not applicable for this formulation, but provided for context).
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
No specific dose adjustment required for renal impairment; however, use with caution if GFR <30 m L/min due to risk of accumulation of nicardipine metabolites.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
In patients with cirrhosis and clinically significant portal hypertension (Child-Pugh class B or C), reduce initial dose to 0.5 mg/h and titrate cautiously. Monitor for hypotension and bradycardia.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Not FDA-approved for pediatric use. Limited data: initial dose 0.5-1 mcg/kg/min continuous infusion, titrate up to 3-5 mcg/kg/min for hypertension.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Start at lower initial infusion rate (3 mg/h) and titrate slowly due to decreased clearance and increased sensitivity to hypotension. Monitor closely for adverse effects.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
None
None.
Use caution in patients with coronary artery disease: may increase frequency, duration, or severity of angina during initiation or upward titration.,Hypotension: monitor blood pressure closely; particularly in patients with reduced left ventricular function.,Hepatic impairment: reduced clearance; consider dose reduction and monitor liver function.,Renal impairment: may require dose adjustment; monitor renal function.,Ventricular ectopy and ventricular tachycardia have been reported, especially in patients with preexisting conduction abnormalities.,Avoid abrupt discontinuation; taper gradually to prevent rebound hypertension.,Use with beta-blockers: increased risk of heart failure; monitor cardiac function.
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hypersensitivity to nicardipine or any component of the formulation.,Severe hypotension (systolic blood pressure <90 mm Hg).,Cardiogenic shock or decompensated heart failure.,Advanced aortic stenosis (may reduce coronary perfusion).,Concurrent use with strong CYP3A4 inducers (e.g., rifampin) or inhibitors (e.g., ketoconazole) requires caution; contraindicated if coadministration with certain strong inhibitors leads to severe hypotension.
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
Grapefruit and grapefruit juice are contraindicated as they increase nicardipine levels via CYP3A4 inhibition. High-fat meals may reduce absorption when taken orally, but IV route bypasses this. Avoid excessive sodium intake as it may counteract antihypertensive effects.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Pregnancy Category C. First trimester: No adequate human studies; animal studies show teratogenicity (skeletal, cardiovascular) at high doses. Second/third trimesters: Risk of fetal hypoxia due to maternal hypotension; calcium channel blockers may inhibit uterine contractions. Use only if potential benefit outweighs risk.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE enters breast milk in low concentrations (M/P ratio approximately 0.7). No adverse effects reported in infants; however, caution advised. Monitor infant for hypotension, bradycardia.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
Increased volume of distribution and clearance in pregnancy may necessitate higher doses; however, titration to effect is recommended due to hypotension risk. Start at low doses and increase gradually.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
For acute hypertension, administer as a continuous IV infusion (5 mg/hr, titrate up to 15 mg/hr). Monitor blood pressure every 5-15 minutes during titration. Use cautiously in advanced aortic stenosis; may precipitate angina. Extravasation can cause tissue necrosis; ensure central line access if peripheral infusion is prolonged. Nicardipine is photolabile; protect infusion bag from light and discard after 24 hours. In hepatic impairment or elderly, start at 3 mg/hr to avoid hypotension.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
Report any chest pain, irregular heartbeat, or dizziness immediately.,Avoid sudden standing to prevent orthostatic hypotension.,This medication is given intravenously; you will be monitored closely.,Notify nurse if you experience pain, redness, or swelling at the IV site.,Do not eat grapefruit or drink grapefruit juice while on this medication.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Ximelagatran, a prodrug of the direct thrombin inhibitor melagatran, is primarily metabolized by CYP450 enzymes, particularly CYP2C9 and to a lesser extent CYP3A4. Nicardipine, a dihydropyridine calcium channel blocker, is extensively metabolized by CYP3A4. Coadministration of ximelagatran with nicardipine may result in inhibition of CYP3A4-mediated metabolism of nicardipine, leading to increased nicardipine plasma concentrations, enhanced hypotensive effects, and potentially elevated risk of adverse events such as edema, headache, and dizziness."
"Cinnarizine, a piperazine derivative with antihistaminic and calcium channel-blocking properties, inhibits cytochrome P450 (CYP) 3A4, the primary enzyme responsible for the metabolism of nicardipine, a dihydropyridine calcium channel blocker. This inhibition leads to reduced clearance and elevated plasma concentrations of nicardipine, potentially resulting in enhanced vasodilation, hypotension, reflex tachycardia, and increased risk of adverse effects such as peripheral edema, dizziness, and headache. Clinically, patients may experience exaggerated hypotensive responses and cardiovascular instability."
"Etoricoxib, a selective COX-2 inhibitor, can inhibit the metabolism of nicardipine, a dihydropyridine calcium channel blocker, via competitive inhibition of CYP3A4. This results in elevated plasma concentrations of nicardipine, potentially leading to enhanced hypotensive effects and an increased risk of adverse events such as dizziness, headache, peripheral edema, and reflex tachycardia. Clinically, this interaction may necessitate dose adjustment and careful monitoring of blood pressure and heart rate."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE is a Electrolyte that works by Nicardipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It has greater selectivity for vascular smooth muscle than for cardiac muscle, leading to vasodilation and reduced peripheral vascular resistance. It does not significantly affect sinoatrial nodal or atrioventricular conduction.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE is: Administer intravenously at an initial rate of 5 mg/h, titrated by increasing by 2.5 mg/h every 5-15 minutes to a maximum of 15 mg/h for hypertension. For substitution of oral therapy, start at 0.5 mg/h and titrate to achieve desired blood pressure.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE is classified as Category A/B. Pregnancy Category C. First trimester: No adequate human studies; animal studies show teratogenicity (skeletal, cardiovascular) at high doses. Second/third trimesters: Risk of feta. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.